Tuberculosis disease (TD) is caused by the activation of latent TB infection (LTBI). LTBI is noninfectious and asymptomatic but can be treated to reduce the probability of progression to disease. With over 15 million persons in the United States infected with LTBI, prioritizing high risk groups for LTBI testing and treatment is essential to feasibly and cost effectively controlling the spread of TB. This dissertation comprises three essays that will help policymakers decide who, how and why to test and treat for LTBI.
This document was submitted as a dissertation in June 2015 in partial fulfillment of the requirements of the doctoral degree in public policy analysis at the Pardee RAND Graduate School. The faculty committee that supervised and approved the dissertation consisted of Emmett Keeler (Chair), Shanthi Nataraj, and Ricardo Basurto-Davila.
This report is part of the RAND Corporation dissertation series. Pardee RAND dissertations are produced by graduate fellows of the Pardee RAND Graduate School, the world's leading producer of Ph.D.'s in policy analysis. The dissertations are supervised, reviewed, and approved by a Pardee RAND faculty committee overseeing each dissertation.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.